RxDoctor Payments Data

Irene Gabrial, MD

Psychiatry · Hamilton, NJNPI 1710074158

Payments from drug & device makers

$1,527in general payments, 2019–2025

Across 42 payments — averaging $36.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$490
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$304
  • AbbVie$178
  • Neurocrine Biosciences, Inc.$161
  • Alkermes, Inc.$111
  • Takeda Pharmaceuticals U.S.A., Inc.$83
  • plus $201 from 6 others

What the payments were for

  • Food & beverage$1,527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,527 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,480
Medicare patients
23
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$104,000
Abilify MaintenaAripiprazole25$64,907
Risperidone ErRisperidone Microspheres22$21,597
Lurasidone Hcl22$10,374
BelsomraSuvorexant12$4,918
Quetiapine Fumarate ErQuetiapine Fumarate91$4,239
Aripiprazole87$4,012
Paliperidone ErPaliperidone23$2,659
Venlafaxine Hcl ErVenlafaxine Hcl80$2,302
Quetiapine Fumarate220$2,148
Ziprasidone Hcl53$2,027
Duloxetine Hcl75$1,730
Bupropion XlBupropion Hcl87$1,442
Olanzapine OdtOlanzapine15$1,414
Trazodone Hcl285$1,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$490$64,90725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →